One of the biggest myths regarding the proposed International Pricing Index Model is that it will have little to no effect on biomedical research and development (R&D). In fact, a recent survey of PhRMA member companies found many expect the proposal to greatly affect their R&D. Here are some of the key findings from survey respondents:

- **77%** of companies said that if the proposal goes through, it will affect their ability to pursue current or future R&D projects.

- **92%** of companies saw a risk of reducing investments in all Part B medicines, which are primarily biologics that are administered by physicians and used to treat many diseases like multiple sclerosis, rheumatoid arthritis, cancer and genetic disorders.

- **88%** of companies said cell and gene therapy projects could be affected.

- **70%** of companies expected significant cuts in cancer R&D.

- **HALF** of the companies reported that 20% or more of their current projects could be reduced or terminated.

- **66%** of companies expressed concern about near-term job cuts, the eventual closure of facilities or abandonment of expansion plans.

Learn more at [PhRMA.org/PartB](https://PhRMA.org/PartB)

Source: Survey commissioned by PhRMA and conducted in December 2018 by the law firm of Manatt, Phelps & Phillips, LLP.